David Russler-Germain

Medicine & Life Sciences

1. Acute Myeloid Leukemia 100%
2. Natural Killer Cells 96%
3. DNA methyltransferase 3A 86%
4. Memory 76%
5. Cell Transplantation 70%
6. Mutation 55%
7. Methyltransferases 48%
8. Tissue Donors 46%
9. Myeloid Cells 44%
10. Immunoconjugates 40%
11. Electron Microscope Tomography 38%
12. fludarabine 37%
13. Immunotherapy 34%
14. Haploinsufficiency 33%
15. Transplants 32%
16. Acute Promyelocytic Leukemia 32%
17. Methylation 32%
18. Cell Polarity 32%
19. Neoplasms 32%
20. Melphalan 31%
21. CpG Islands 31%
22. Demethylation 31%
23. Patient Transfer 30%
24. Leukemia 28%
25. Ferritins 27%
26. B-Cell Lymphoma 27%
27. Cell- and Tissue-Based Therapy 26%
28. Microtubules 25%
29. Lymphoma 25%
30. Non-Hodgkin's Lymphoma 24%
31. Histones 24%
32. Cyclophosphamide 24%
33. Cell Differentiation 23%
34. Iron 21%
35. Melanoma 21%
36. Gene Fusion 19%
37. T-Lymphocytes 19%
38. Fats 19%
39. Direction compound 18%
40. Hematopoietic Stem Cells 16%
41. Pediatrics 16%
42. polatuzumab vedotin 16%
43. Proteins 16%
44. Neurons 16%
45. Loss of Function Mutation 15%
46. alpha-hydroxyglutarate 13%
47. Brentuximab Vedotin 13%
48. Antigens 13%
49. Clinical Trials 13%
50. Mortality 13%